Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus SYNACORT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus SYNACORT.
CORTIFOAM vs SYNACORT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
Synthetic corticosteroid with potent glucocorticoid activity; binds to glucocorticoid receptors, modulating gene expression to suppress inflammation, immune response, and adrenal function.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
100 mg intravenously every 8 hours for 24 hours, then 50 mg intravenously every 8 hours for 48 hours, followed by 25 mg intravenously every 8 hours for 72 hours.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Terminal elimination half-life is 2.5–3.5 hours; clinically, this short half-life requires multiple daily dosing for sustained effects.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Primarily renal (80% as metabolites, 20% unchanged); minor biliary/fecal (<5%).
Category C
Category C
Corticosteroid
Corticosteroid